The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death
Open accessAbstract
Nutrient deprivation has been shown to cause cancer cell death. To exploit nutrient deprivation as anti-cancer therapy, we investigated the effects of the anti-metabolite 2-deoxy-D-glucose on breast cancer cells in vitro. This compound has been shown to inhibit glucose metabolism. Treatment of human breast cancer cell lines with 2-deoxy-D-glucose results in cessation of cell growth in a dose dependent manner. Cell viability as measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide conversion assay and clonogenic survival are decreased with 2-deoxy-D-glucose treatment indicating that 2-deoxy-D-glucose causes breast cancer cell death. The cell death induced by 2-deoxy-D-glucose was found to be due to apoptosis as demonstrated by induction of caspase 3 activity and cleavage of poly (ADP-ribose) polymerase. Breast cancer cells treated with 2-deoxy-D-glucose express higher levels of Glut1 transporter protein as measured by Western blot analysis and have increased glucose uptake compared to non-treated breast cancer cells. From these results we conclude that 2-deoxy-D-glucose treatment causes death in human breast cancer cell lines by the activation of the apoptotic pathway. Our data suggest that breast cancer cells treated with 2-deoxy-D-glucose accelerate their own demise by initially expressing high levels of glucose transporter protein, which allows increased uptake of 2-deoxy-D-glucose, and subsequent induction of cell death. These data support the targeting of glucose metabolism as a site for chemotherapeutic intervention by agents such as 2-deoxy-D-glucose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Carmichael, J., DeGraff, W., Gazdar, A. F., Minna, J. D., & Mitchell, J. B. (1987) · PubMed · Cited by 3,813
BCL-2 family members and the mitochondria in apoptosis
Gross, A., McDonnell, J. M., & Korsmeyer, S. J. (1999) · Genes & Development · doi:10.1101/gad.13.15.1899 · Cited by 3,641
Bcl-2 functions in an antioxidant pathway to prevent apoptosis
Hockenbery, D. M., Oltvai, Z. N., Yin, X.-M., Milliman, C. L., & Korsmeyer, S. J. (1993) · Cell · doi:10.1016/0092-8674(93)80066-n · Cited by 3,419
An alternative, nonapoptotic form of programmed cell death
Sperandio, S., de Belle, I., & Bredesen, D. E. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.26.14376 · Cited by 1,006
Gottlob, K., Majewski, N., Kennedy, S., Kandel, E., Robey, R. B., & Hay, N. (2001) · Genes & Development · doi:10.1101/gad.889901 · Cited by 961
Deregulation of Glucose Transporter 1 and Glycolytic Gene Expression by c-Myc
Osthus, R. C., Shim, H., Kim, S., Li, Q., Reddy, R., Mukherjee, M., Xu, Y., Wonsey, D., Lee, L. A., & Dang, C. V. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000023200 · Cited by 879
Flier, J. S., Mueckler, M. M., Usher, P., & Lodish, H. F. (1987) · Science · doi:10.1126/science.3103217 · Cited by 786
Localization of the primary metabolic block produced by 2-deoxyglucose
Wick, A. N., Drury, D. R., Nakada, H. I., Wolfe, J. B., Britton, B., & Grabowski, R. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64988-9 · Cited by 780 · cited 2×
“2-DG-6-P is not a substrate for glucose-6-phosphate dehydrogenase or phosphohexoisomerase (Wick et al, 1957).”
BackgroundWeber, G. (1977) · New England Journal of Medicine · doi:10.1056/nejm197703032960905 · Cited by 641
Cited by
Fantin, V. R., St-Pierre, J., & Leder, P. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.023 · Cited by 1,635
“Isolation of tumor cell lines with stable knockdown of LDH-A Sensitivity to glucose deprivation as well as elevated LDH-A activity has been well documented in a variety of human breast cancer cell lines and tissue sections, respectively (Aft et al., 2002; Balinsky et al., 1983).”
BackgroundTargeting cancer metabolism: a therapeutic window opens
Vander Heiden, M. G. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3504 · Cited by 1,411
2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents
Pajak, B., Siwiak, E., Sołtyka, M., Priebe, A., Zieliński, R., Fokt, I., Ziemniak, M., Jaśkiewicz, A., Borowski, R., Domoradzki, T., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010234 · Cited by 574
Rathmell, J. C., Fox, C. J., Plas, D. R., Hammerman, P. S., Cinalli, R. M., & Thompson, C. B. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.20.7315-7328.2003 · Cited by 572
“In addition, suppression of glucose transport and glucose metabolism have been shown to inhibit tumor growth (1, 44).”
BackgroundCancer Metabolism: Phenotype, Signaling and Therapeutic Targets
Park, J. H., Pyun, W. Y., & Park, H. W. (2020) · Cells · doi:10.3390/cells9102308 · Cited by 548
Tumor glycolysis, an essential sweet tooth of tumor cells
Paul, S., Ghosh, S., & Kumar, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.09.007 · Cited by 449
The Ketogenic Diet as a Treatment Paradigm for Diverse Neurological Disorders
Stafstrom, C. E., & Rho, J. M. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00059 · Cited by 438
Role of glucose and ketone bodies in the metabolic control of experimental brain cancer
Seyfried, T. N., Sanderson, T. M., El-Abbadi, M. M., McGowan, R., & Mukherjee, P. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601269 · Cited by 267
Liao, M., Yao, D., Wu, L., Luo, C., Wang, Z., Zhang, J., & Liu, B. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.12.003 · Cited by 261
Mirzayans, R., Andrais, B., Scott, A., & Murray, D. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/170325 · Cited by 257
Long, Y., Tsai, W.-B., Wangpaichitr, M., Tsukamoto, T., Savaraj, N., Feun, L. G., & Kuo, M. T. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0302 · Cited by 121
“Since ADI cells exhibit elevated expression of Glut1 and enhanced glucose uptake, known as the Warburg effect, we asked whether these cells would be preferentially killed by 2-DG, a commonly used inhibitor of glycolysis (26-28).”
BackgroundGut microbiome catabolites as novel modulators of muscle cell glucose metabolism
Houghton, M. J., Kerimi, A., Mouly, V., Tumova, S., & Williamson, G. (2019) · The FASEB Journal · doi:10.1096/fj.201801209r · Cited by 92
Giammarioli, A. M., Gambardella, L., Barbati, C., Pietraforte, D., Tinari, A., Alberton, M., Gnessi, L., Griffin, R. J., Minetti, M., & Malorni, W. (2012) · International Journal of Cancer · doi:10.1002/ijc.26420 · Cited by 65
Targeting endothelial metabolism for anti-angiogenesis therapy: A pharmacological perspective
Missiaen, R., Morales-Rodriguez, F., Eelen, G., & Carmeliet, P. (2017) · Vascular Pharmacology · doi:10.1016/j.vph.2017.01.001 · Cited by 58
Lucantoni, F., Dussmann, H., & Prehn, J. H. M. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00113 · Cited by 47
Wokoun, U., Hellriegel, M., Emons, G., & Gründker, C. (2017) · Oncology Reports · doi:10.3892/or.2017.5491 · Cited by 45
“2DG is a glucose analog, which leads to inhibition of glycolysis and a decrease in ATP production resulting in induction of apoptosis through activation of caspase-3 in solid tumors (4-8).”
Background
Metadata
- Authors
- Aft, R. L., Zhang, F. W., & Gius, D.
- Venue
- British Journal of Cancer
- Published
- 2002-09
- Volume
- 87
- Issue
- 7
- Pages
- 805-812
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2092752244
- Cited by
- 305
- References
- 67
- FWCI
- 1.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.